--- canonical_url: https://www.stockexpertai.com/earnings/cvs last_updated: 2026-07-07T06:15:59.116Z --- # CVS Health Corp. (CVS) Q4 FY2026 Earnings Preview > This content was automatically generated with FMP live data + Q1 FY2026 earnings call transcript. Generated: 2026-07-07T06:15:57.773Z. Educational tool, not investment advice. --- ## Quick Summary | Field | Value | Source | |---|---|---| | Price | $102.08 (▼ -2.52%) | fmp:quote | | Market Cap | $130.2B | fmp:profile | | 52w range | $58.50 – $106.15 | fmp:quote | | Earnings | Thu 30 Jul | fmp:earnings-history | | EPS estimate | $1.86 (+3% YoY) | fmp:earnings-estimate | | Revenue estimate | $100.2B | fmp:earnings-estimate | | Beat streak | 6/4 | fmp:earnings-history | | Rating | B+ (overall 3/5) | fmp:ratings | | Analyst median target | $106 (+3.8% upside) | fmp:price-target-consensus | | MoonshotScore | 46/100 | derived | | Council | 2/6 bullish | derived | | Munger verdict | Fairly Valued | derived | ## CVS Health Corp. — Q4 FY2026 Expectations Q4 consensus: revenue $100.2B^{[FMP est]}, EPS $1.86^{[FMP est]}. 6 consecutive quarters of beat^{[FMP earnings]}. ## Quick Take **Score:** B+ · **Stance:** HOLD · **Council:** 2/6 · **Moonshot:** 46 = MoonshotScore 46^{[9-pillar formula]} + Council 2/6^{[6-lens rule]}. Form 4: 0 transactions^{[FMP Form 4]}. ## Watchlist (5 metrics) ### 1. Fy26 Eps Guidance Increase CVS Health raised its full year 2026 adjusted earnings per share (EPS) guidance to a range of $7.30 to $7.50 following strong first-quarter performance. > "Our strong first quarter performance gave us the confidence to increase our full year 2026 adjusted earnings per share guidance to a range of $7.30 to $7.50, up from the previous range of $7 to $7.20." > — David Joyner, Chair and Chief Executive Officer, Expectation / Guide · Q1 FY2026 ### 2. Cash Flow Leverage CVS Health generated $4.2 billion in cash flow from operations in the first quarter and improved its leverage ratio to 3.84x, demonstrating strong financial health and capacity to return value to shareholders. > "In the first quarter, we generated cash flows from operations of approximately $4.2 billion and returned nearly $850 million to our shareholders through our quarterly dividend. Our leverage ratio at the end of the first quarter improved to 3.84x." > — Brian Newman, Chief Financial Officer, Investor Focus · Q1 FY2026 ### 3. Aetna Margin Recovery Aetna achieved over $1 billion of year-over-year adjusted operating income improvement in the first quarter due to successful execution of its margin recovery plans. > "We drove over $1 billion of year-over-year AOI improvement at Aetna." > — Brian Newman, Chief Financial Officer, Risk Indicator · Q1 FY2026 ### 4. Prior Authorization Efficiency Aetna leads in operational efficiency by having the fewest medical services subject to prior authorization in the industry, approving over 95% of eligible prior authorizations within 24 hours, with over 80% approved in real time. > "Aetna has the fewest medical services subject to prior authorization in the industry. Our focus on embedding technology within each of our businesses has enabled us to approve more than 95% of the eligible prior authorizations within 24 hours, with over 80% being approved in real time." > — David Joyner, Chair and Chief Executive Officer, Investor Focus · Q1 FY2026 ### 5. Biosimilar Adoption Strategy CVS Health will exclude branded STELARA from its commercial formularies starting July 1, 2026, replacing it with low-cost biosimilars, aiming to replicate the over 90% patient conversion success achieved with HUMIRA. > "We recently announced that on July 1, 2026, we will exclude branded STELARA from our commercial template formularies to be replaced with the low-cost, effective biosimilars. We'll use the same proven playbook that allowed us to be the only ones to meaningfully move share with HUMIRA, converting over 90% of eligible patients." > — David Joyner, Chair and Chief Executive Officer, Investor Focus · Q1 FY2026 ## MoonshotScore Pillars | Pillar | Score | Level | Evidence | |---|---|---|---| | Revenue Growth | 1.0 | weak | Q1 vs Q2: growth slowing (+1.5%, below threshold) | | Gross Margin | 2.0 | weak | Q1: low margin (15.6%, capital-intensive or commodity) | | Operating Leverage | 0.0 | weak | op margin weak (4.7%, under pressure) | | Cash Runway | 10.0 | strong | FCF very strong ($3.4B, 4.0× CapEx) | | R&D Intensity | 3.0 | weak | low R&D investment (0.0%, weak innovation) | | Price Momentum | 7.0 | strong | RSI 59.1 positive momentum, 50d above | | News Sentiment | 9.0 | strong | strong buy consensus (86%) | **Formula:** sum(pillar.score) / (count * 10) * 100. Each pillar deterministic from FMP. Source maps in pillar.formula. ## Council (7-Lens) | Name | Stance | Context | |---|---|---| | Ray Dalio | bull | macro · target upside +3.8% | | Ken Griffin | bull | flow · 50d MA above | | Jim Simons | neutral | quant · RSI 59 | | Klarman | neutral | value · target upside +3.8% | | Buffett | neutral | quality · ROE score 3/5 | | Munger | neutral | valuation · target upside +3.8% | **Formula:** Each lens uses deterministic rule on bundle data. Logged in member.contextTr. ## Munger Lens - **Verdict:** Fairly Valued - **Financial Health:** Moderate - **Margin of Safety:** Weak - **Interest Coverage:** Adequate - **ROIC vs WACC:** Tight **Formula:** verdict=upside>25?Undervalued:>0?Fairly Valued:Overvalued. Each lens deterministic from FMP ratings + priceTarget. ## Technical Levels - **RSI(14):** 59.1 — yükselişte nötr — overbought sınırının altında, momentum pozitif - **50d MA:** $94 — hisse %8.7 üstünde — kısa vadeli destek - **200d MA:** $82 — hisse %24.9 üstünde — uzun vadeli destek - **Volume (10d):** -21% ## Past Performance (4 Quarters) | Quarter | EPS Actual | EPS Estimate | Result | Reaction | |---|---|---|---|---| | Q2 FY25 | $1.81 | $1.46 | BEAT | +0.6% | | Q3 FY25 | $1.60 | $1.37 | BEAT | -4.9% | | Q4 FY25 | $1.09 | $1.00 | BEAT | +1.9% | | Q1 FY26 | $2.57 | $2.18 | +17.9% EPS | +0.6% | Q1 (May 7, 2026): EPS $2.57 vs $2.18 est^[FMP], +17.9% beat. D+1 movement: +0.6%^{[FMP D+1]}. Decline despite beat — market reacted to guidance, not numbers. ## 3 Scenarios ### Scenario A · Beat **Q4 EPS > $1.86 + CapEx discipline** Threshold: EPS > $1.86^{[FMP est]}. Target: Break above median target $106^{[FMP target]}; high target $115^[FMP] upper bound. ### Scenario B · In-Line **EPS ≈ $1.86 + CapEx < $849.0M** Threshold: EPS ≈ $1.86^{[FMP est]}, Q4 CapEx < $849.0M^[FMP]. Target: Consolidation in the band between current $102^[FMP] and median $106^[FMP]. ### Scenario C · Miss **EPS < $1.80 or CapEx ≥ $849.0M** Threshold: EPS < $1.80^{[FMP est×0.97]}. Target: Current $102 below SMA200 $82^[FMP], if rejection continues, $69^[derived] support activates. ## Risk Notes ### Primary segment below threshold Q1: EPS $2.57 vs $2.18 beat^[FMP], stock +0.6% D+1^[FMP]. ### Backlog concentration No RPO/backlog concentration disclosed in Q1 earnings call. ### Insider trading Form 4 data is marked in the table — this page does not generate assumptions for this stock. | Executive | Action | Amount | Date | |---|---|---|---| **Net:** — (0 transactions · 0 sells · 0 buys) · Q1 FY26 ### CapEx shock Q1 CapEx $849.0M^{[FMP cashflow]}. Q1 op margin 4.7%^{[FMP op margin]} — this level in Q4 is sensitive to CapEx revision risk. ## Wall Street Consensus - **Median target:** $106 (+3.8% upside vs current $102) - **High / Low:** $115 / $90 - **Buy / Hold / Sell:** 24 / 4 / 0 - **Analyst count:** 14 (last quarter), 81 all-time ## Additional Transcript Insights ### 1. fy26_eps_guidance_increase **Claim:** CVS Health raised its full year 2026 adjusted earnings per share (EPS) guidance to a range of $7.30 to $7.50 following strong first-quarter performance. **Evidence (transcript):** "Our strong first quarter performance gave us the confidence to increase our full year 2026 adjusted earnings per share guidance to a range of $7.30 to $7.50, up from the previous range of $7 to $7.20." **Numbers:** $7.30, $7.50, $7, $7.20 ### 2. aetna_margin_recovery **Claim:** Aetna achieved over $1 billion of year-over-year adjusted operating income improvement in the first quarter due to successful execution of its margin recovery plans. **Evidence (transcript):** "We drove over $1 billion of year-over-year AOI improvement at Aetna." **Numbers:** $1 billion ### 3. biosimilar_adoption_strategy **Claim:** CVS Health will exclude branded STELARA from its commercial formularies starting July 1, 2026, replacing it with low-cost biosimilars, aiming to replicate the over 90% patient conversion success achieved with HUMIRA. **Evidence (transcript):** "We recently announced that on July 1, 2026, we will exclude branded STELARA from our commercial template formularies to be replaced with the low-cost, effective biosimilars. We'll use the same proven playbook that allowed us to be the only ones to meaningfully move share with HUMIRA, converting over 90% of eligible patients." **Numbers:** July 1, 2026, 90% ### 4. prior_authorization_efficiency **Claim:** Aetna leads in operational efficiency by having the fewest medical services subject to prior authorization in the industry, approving over 95% of eligible prior authorizations within 24 hours, with over 80% approved in real time. **Evidence (transcript):** "Aetna has the fewest medical services subject to prior authorization in the industry. Our focus on embedding technology within each of our businesses has enabled us to approve more than 95% of the eligible prior authorizations within 24 hours, with over 80% being approved in real time." **Numbers:** 95%, 24 hours, 80% ### 5. health100_ai_platform **Claim:** CVS Health will launch Health100 later this year, an AI-native technology and service platform designed to seamlessly connect any payer, PBM, pharmacy, or provider. **Evidence (transcript):** "Later this year, we will be launching Health100, an AI native, state-of-the-art technology and service platform that allows for any payer, PBM, pharmacy or provider to seamlessly connect." **Numbers:** — ### 6. cash_flow_leverage **Claim:** CVS Health generated $4.2 billion in cash flow from operations in the first quarter and improved its leverage ratio to 3.84x, demonstrating strong financial health and capacity to return value to shareholders. **Evidence (transcript):** "In the first quarter, we generated cash flows from operations of approximately $4.2 billion and returned nearly $850 million to our shareholders through our quarterly dividend. Our leverage ratio at the end of the first quarter improved to 3.84x." **Numbers:** $4.2 billion, $850 million, 3.84x --- *Data source: FMP (live query, 2026-07-07), Q1 FY2026 earnings call transcript (Translated to EN with Gemini 2.0 Flash). Educational tool, not investment advice.*